REPETITIVE INTRACRANIAL INJECTION OF NATURAL KILLER CELLS ENGINEERED WITH A HER2-TARGETED CHIMERIC ANTIGEN RECEPTOR ALONE AND IN COMBINATION WITH SYSTEMIC ANTI-PD-1 CHECKPOINT INHIBITION IN PATIENTS WITH RECURRENT GLIOBLASTOMA

Cytotherapy 2026

View at publisher
Authors: M. Burger, E. Ehrend, F. Straßheimer, P. Çakmak, H. Krenzlin, P. Elleringmann, P. Zeiner, S.C. Herkt, I. Poschke, J. Macas, K. Weber, J. Schupp
+33 more J. Lun, C. Opitz, B. Roller, P. Manns, S. Klinsing, S. Breuer, S. Hehlgans, S. W. Lee, I. Mildenberger, G. Ludmirski, J. Hermann, E. Müller, M. Schmitz, M. Mehlitz, C. Senft, P. Harter, M. Rieger, F. Rödel, M. Czabanka, M. Ratliff, M. Platten, C. Herold-Mende, F. Ringel, E. Herrmann, E. Hattingen, Y. Reiss, L. Bunse, H. Bönig, KH Plate, M. Forster, W.S. Wels, J. Steinbach, T. Tonn
DOI: 10.1016/j.jcyt.2026.102167
Cited by: 1

Fields of Study & Subjects

Immunotherapy and Immune Responses Glioma Diagnosis and Treatment Angiogenesis and VEGF in Cancer

Publication details

Journal / source
Cytotherapy
Publisher
Elsevier BV
Volume
28
Issue
5
Pages
102167–102167
Publication date
30 April 2026
Language
EN